CD8A and neoplasm: Preliminary data published for 62 patients treated with up to 4 mg/kg XTX202 shows an increase in CD8+ T cells in the tumor across all dose levels as well as a dose dependent increase of CD8+ T cell and NK cell proliferation in the periphery.